Angiotensin Receptor Blockers Versus Calcium Channel Blockers for First‐Line Antihypertensive Therapy and Survival in Adults Aged 75 Years or Older

BACKGROUND: Evidence guiding first-line antihypertensive drug choice in adults aged 75 years or older is limited, despite widespread use of angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs) in late older age. METHODS: We conducted a target trial emulation using a new-user design in a nationwide linked healthcare claims database in Japan. Adults aged ≥ 75 years who had no prescription of either drug class in the preceding 12 months and initiated an ARB (n = 10,037) or a CCB (n = 19,785) were followed from treatment initiation. The primary outcome was all-cause mortality; secondary outcomes included hospitalization for heart failure, myocardial infarction, stroke, and major adverse cardiovascular events (MACE). Intention-to-treat effects were estimated using inverse probability of treatment and censoring weighting with pooled logistic regression models. RESULTS: Among 29,822 patients, median follow-up was 4.0 years. During follow-up, 3487 deaths occurred. ARB therapy was associated with lower all-cause mortality than CCB therapy (hazard ratio [HR], 0.885; 95% CI, 0.823-0.951). The estimated 5-year risk of death was 12.7% for ARB users and 14.8% for CCB users (absolute risk difference, -2.1 percentage points; 95% CI, -3.1 to -1.0). ARB therapy was also associated with lower risks of heart failure hospitalization (HR, 0.843; 95% CI, 0.774-0.918), myocardial infarction (HR, 0.867; 95% CI, 0.795-0.945), stroke (HR, 0.931; 95% CI, 0.869-0.998), and MACE (HR, 0.889; 95% CI, 0.848-0.931). Associations were consistent across age subgroups, including adults aged ≥ 85 years. CONCLUSION: In adults aged 75 years or older, ARB-based antihypertensive therapy was associated with lower risks of mortality and cardiovascular events compared with CCB-based therapy. These findings suggest that first-line antihypertensive drug choice may have prognostic implications in late older age.

Authors

Institutions

Publication Details

Journal
Journal of the American Geriatrics Society
Published
2026-04-26
DOI
https://doi.org/10.1111/jgs.70463
Primary Topic
Blood Pressure and Hypertension Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Angiotensin Receptor Blockers Versus Calcium Channel Blockers for First‐Line Antihypertensive Therapy and Survival in Adults Aged 75 Years or Older

Hiroshi Sunada, Taiki Sugimoto, Futoshi Oda, Ken‐ei Sada et al.
Journal of the American Geriatrics Society
Blood Pressure and Hypertension Studies
article

Angiotensin Receptor Blockers Versus Calcium Channel Blockers for First‐Line Antihypertensive Therapy and Survival in Adults Aged 75 Years or Older

Hiroshi Sunada, Taiki Sugimoto, Futoshi Oda, Ken‐ei Sada, Haruhisa Fukuda, Hisashi Noma, Megumi Maeda
article en

Abstract

BACKGROUND: Evidence guiding first-line antihypertensive drug choice in adults aged 75 years or older is limited, despite widespread use of angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs) in late older age. METHODS: We conducted a target trial emulation using a new-user design in a nationwide linked healthcare claims database in Japan. Adults aged ≥ 75 years who had no prescription of either drug class in the preceding 12 months and initiated an ARB (n = 10,037) or a CCB (n = 19,785) were followed from treatment initiation. The primary outcome was all-cause mortality; secondary outcomes included hospitalization for heart failure, myocardial infarction, stroke, and major adverse cardiovascular events (MACE). Intention-to-treat effects were estimated using inverse probability of treatment and censoring weighting with pooled logistic regression models. RESULTS: Among 29,822 patients, median follow-up was 4.0 years. During follow-up, 3487 deaths occurred. ARB therapy was associated with lower all-cause mortality than CCB therapy (hazard ratio [HR], 0.885; 95% CI, 0.823-0.951). The estimated 5-year risk of death was 12.7% for ARB users and 14.8% for CCB users (absolute risk difference, -2.1 percentage points; 95% CI, -3.1 to -1.0). ARB therapy was also associated with lower risks of heart failure hospitalization (HR, 0.843; 95% CI, 0.774-0.918), myocardial infarction (HR, 0.867; 95% CI, 0.795-0.945), stroke (HR, 0.931; 95% CI, 0.869-0.998), and MACE (HR, 0.889; 95% CI, 0.848-0.931). Associations were consistent across age subgroups, including adults aged ≥ 85 years. CONCLUSION: In adults aged 75 years or older, ARB-based antihypertensive therapy was associated with lower risks of mortality and cardiovascular events compared with CCB-based therapy. These findings suggest that first-line antihypertensive drug choice may have prognostic implications in late older age.

Journal of the American Geriatrics Society
Kyushu University (JP), The Graduate University for Advanced Studies, SOKENDAI (JP), Kochi Medical School Hospital (JP), Tottori University Hospital (JP), The Institute of Statistical Mathematics (JP), National Center for Geriatrics and Gerontology (JP)
Japan Society for the Promotion of Science, Japan Science and Technology Agency
Good health and well-being
Openalex Percentile: Top 6%
Blood Pressure and Hypertension Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.